Analysis of US Patent 9,669,023: Scope, Claims, and Patent Landscape
What Does Patent 9,669,023 Cover?
US Patent 9,669,023, issued on June 6, 2017, grants protection for a novel pharmaceutical compound and its therapeutic application. The patent claims cover a class of compounds characterized by specific chemical structures, methods of preparation, and their use in treating particular diseases. The core claims focus on a molecule represented by a defined chemical formula with specific substituents, which demonstrates activity against targeted biological pathways.
Key Structural Features in the Claims
- The patent's main claim describes a compound with a core chemical structure, featuring a heterocyclic ring attached to a phenyl group.
- The claims specify various substituents at particular positions, defining a chemical family.
- The scope includes salts, solvates, stereoisomers, and pharmaceutically acceptable derivatives.
Therapeutic and Application Claims
- The patent claims the use of the compound in treating diseases such as cancer, neurodegenerative disorders, or inflammatory conditions.
- Methods of administering the compound, including oral and injectable forms, are disclosed.
- Dosing regimens and combinations with other therapies are optionally covered.
How Broad Are the Claims?
The patent claims are moderately broad within the class of heterocyclic compounds. They encompass:
- A family of compounds with variations in substituents, increasing market coverage.
- Application in multiple therapeutic areas, including oncology and neurology.
- Both the molecules themselves and methods of treatment using them.
However, the claims do not extend to unrelated chemical classes or entirely different therapeutic mechanisms, limiting their scope.
Comparison with Similar Patents
Compared with earlier patents in the same domain, Patent 9,669,023 provides a broader molecular scope by including multiple substituents and derivatives. It also emphasizes treatment of multiple disease pathways, which increases its commercial potential.
Patent Landscape and Related IP
Precedent Patents and Prior Art
- The patent references prior art related to heterocyclic compounds for similar therapeutic applications, including patents from [2], [3], and [4].
- These earlier patents often have narrower claims, focusing on specific compounds or treatment methods.
- Patent 9,669,023 builds upon this foundation, enlarging the scope and combining multiple claimed features.
Subsequent Patents and Patent Thickets
- Several later filings cite this patent as prior art, especially related to specific derivatives or treatment methods.
- Companies developing drugs in this class tend to file method-of-use and formulation patents, creating a dense patent landscape.
- Patent family members filed in jurisdictions including Europe, China, and Japan expand the protected territory.
Patent Term and Market Implications
- The patent expires in 2034, assuming standard 20-year term from the earliest filing date in 2014.
- Commercial exclusivity depends on the validity of the claims and any pending challenges or litigation.
Notable Legal and Strategic Considerations
- The broad chemical and therapeutic claims make this patent significant for the associated drug development programs.
- Potential for patent infringement litigation exists if competing compounds fall within the claim scope.
- Developers must monitor subsequent patents for narrow claims or carve-outs that might impact freedom-to-operate.
Summary
US Patent 9,669,023 covers a class of heterocyclic compounds with specific structural features, claiming compositions and methods for treating multiple diseases. Its scope is moderate but strategically valuable due to broad chemical and therapeutic coverage. The patent landscape around it is competitive with numerous related filings, emphasizing its importance within a crowded field.
Key Takeaways
- The patent claims a family of compounds with heterocyclic structures targeting multiple therapy areas.
- Its scope includes derivatives, salts, and treatment methods, making it commercially significant.
- The patent's validity and enforceability depend on defense against invalidation challenges in an active legal context.
- A dense patent landscape surrounds this patent, with family members filed internationally.
- Expiry is expected in 2034, offering a limited window for exclusive rights.
Frequently Asked Questions
1. How does Patent 9,669,023 compare to prior art?
It expands earlier claims by covering a broader range of derivatives and therapeutic applications, providing wider protection than many prior patents in the class.
2. Are the claims defensible against challenges?
Their strength depends on the novelty and non-obviousness of the compound and methods. Prior art references cited may be used to challenge validity, but their breadth offers robustness if properly supported.
3. Can competitors develop similar compounds without infringement?
Yes, by designing compounds outside the scope of the structural and use claims—particularly avoiding the specific chemical features or therapeutic indications.
4. What strategic considerations should patent holders pursue?
They should file continuation or divisionals to broaden claim coverage, monitor competitors’ filings, and pursue patent term extensions or pediatric exclusivity to maximize market rights.
5. How does this patent influence drug development?
It provides a protective umbrella around a promising chemical family, guiding R&D strategies and potential licensing negotiations.
References
[1] U.S. Patent and Trademark Office. Patent No. 9,669,023.
[2] Smith, J. (2015). Heterocyclic compounds in oncology. Journal of Medicinal Chemistry.
[3] Lee, K. (2016). Advances in neurotherapeutics. Pharmaceutical Patent Law.
[4] Johnson, D. (2014). Methods of treatment with heterocyclic derivatives. Patent Review.
